The Company That Pioneered Off-the-Shelf CAR-T Just Walked Away From It
Cellectis, one of the original pioneers of off-the-shelf CAR-T therapy, just abandoned its two lead programs and pivoted entirely to in vivo gene editing. After a decade of work and zero approvals across the entire allogeneic field, the move raises big questions about the future of donor-derived cell therapy.
Imagine spending a decade building a house, only to tear it down and start building a different one next door. That's essentially what Cellectis just did.
The French biotech, one of the earliest champions of allogeneic ("off-the-shelf") CAR-T cell therapy, announced on September 14 that it's abandoning internal development of its two lead CAR-T programs. Instead, the company is pivoting entirely to in vivo gene editing: a technology that rewires cells inside your body rather than in a factory.
It's a dramatic exit from a field Cellectis helped create. And it raises an uncomfortable question: if one of the pioneers is giving up, what does that say about the whole approach?
A Decade of Promise, Zero Approvals
To understand why this matters, you need a bit of backstory. CAR-T therapy works by engineering a patient's immune cells to hunt cancer. The approved versions (from companies like Novartis and Bristol Myers Squibb) are autologous, meaning they use each patient's own cells. That process is slow, expensive, and highly personalized.
Allogeneic CAR-T was supposed to be the shortcut. Take healthy donor cells, gene-edit them so they won't attack the patient (or get attacked by the patient's immune system), and freeze them in batches. Off the shelf. Ready to go. Think of it as the difference between a custom suit and one you grab at the store.
Cellectis was at the forefront. Its TALEN gene-editing platform was designed to solve the core problems of donor-cell therapy: graft-versus-host disease (where donor cells attack the patient) and host rejection (where the patient's body destroys the donor cells). Back in 2015, Cellectis treated the first infant leukemia patient with a gene-edited allogeneic CAR-T product. It was a genuine scientific milestone.
But milestones don't pay the bills. As of September 2026, no allogeneic CAR-T product has received regulatory approval. Not from Cellectis. Not from Allogene. Not from anyone.
The Problems That Never Got Solved
The fundamental issue is persistence. Donor-derived T cells tend to get cleared by the patient's immune system within days to weeks. That's like hiring a bodyguard who quits after the first shift.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Gene editing can reduce rejection, but it introduces new complications. Multiplex editing (making several genetic changes at once) raises concerns about off-target cuts and regulatory scrutiny. Patients on these trials also face prolonged low blood-cell counts and serious infection risks from the heavy-duty immune suppression required before infusion.
Cellectis had two programs still in the clinic: lasme-cel (targeting B-cell acute lymphoblastic leukemia in its BALLI-01 trial) and eti-cel (targeting non-Hodgkin lymphoma in NATHALI-01). The data wasn't terrible. BALLI-01 showed 14.8 months median overall survival in patients who achieved deep remissions. NATHALI-01 reported an 88% overall response rate and a 63% complete response rate.
So why walk away from numbers like those? Because the market landscape shifted under Cellectis's feet. The company said the addressable patient populations for B-ALL and NHL had "changed materially," making the path to registration slower and more expensive than originally planned. Translation: the competitive math stopped working.
What Cellectis Is Building Instead
The new strategy centers on two preclinical programs that couldn't be more different from cancer immunotherapy. Both target cardiovascular metabolic diseases, not tumors:
HEAL-101 uses base editing to target a gene called APOC3 in patients with severe hypertriglyceridemia (dangerously high triglycerides). HEAL-201 uses epigenetic editing to target PCSK9, a well-known cholesterol gene, for severe hypercholesterolemia.
If PCSK9 sounds familiar, it should. PCSK9 inhibitors like Repatha and Praluent are already blockbuster drugs. The difference is that those require ongoing injections. Cellectis's approach would, in theory, be a one-time treatment that silences the gene permanently.
Both programs are headed for Phase 1 investigator-initiated trials in China. Preliminary data from HEAL-101 is expected in the second half of 2027, with HEAL-201 following in early 2028.
Following the Money (and the Runway)
Let's talk cash. Cellectis reported $169 million in consolidated cash and deposits as of June 30, 2026. The company says the pivot should extend its runway into the second half of 2028, which is convenient timing: that's roughly when the first meaningful clinical data from the new programs would arrive.
The stock was trading around $3.10 on Nasdaq as of September 11. For context, analysts had a 12-month average price target of $7.00, though that was set before this strategic earthquake. With about 224 employees, Cellectis is a small ship that needed to pick a direction. It picked.
Importantly, Cellectis isn't torching every bridge to its CAR-T past. The company said it will seek partners for lasme-cel and eti-cel rather than shelve them entirely. It's also maintaining existing partnerships with AstraZeneca, Allogene, Servier, and Iovance, which license various pieces of its TALEN technology.
The Bigger Picture: An Industry in Motion
Cellectis isn't pivoting in a vacuum. The entire biopharma industry has been sprinting toward in vivo cell therapy over the past two years. The idea is elegant: instead of pulling cells out of a patient, editing them, and putting them back (a weeks-long process), you deliver the genetic instructions directly into the body and let the cells reprogram themselves.
The M&A activity tells the story. AstraZeneca acquired EsoBiotec in 2025 for its in vivo platform. Kite (Gilead's cell therapy arm) bought Interius BioTherapeutics the same year. AbbVie acquired Capstan Therapeutics and Eli Lilly scooped up Orna Therapeutics. Companies like Umoja Biopharma and CARsgen have programs in the clinic already.
Fierce Biotech described Cellectis as joining the "in vivo bandwagon," which is a slightly brutal way to characterize a company that's been doing gene editing since before most of these acquirers knew what CRISPR stood for.
So What Does This Mean?
For patients waiting on allogeneic CAR-T, this is another signal that the off-the-shelf dream remains stubbornly out of reach. The technology isn't dead; other companies are still pursuing it. But when one of the founders walks away, it's hard not to read the room.
For Cellectis specifically, the bet is clear: its gene-editing expertise is better deployed inside the body than inside a manufacturing facility. Whether that bet pays off depends on Phase 1 data that's still more than a year away.
For the broader industry, the pivot is a reminder that biotech strategies have a shelf life, even "off-the-shelf" ones. The technology that excites investors today can become yesterday's thesis faster than you'd expect. Cellectis built the allogeneic CAR-T playbook, and now it's rewriting it from scratch.
Sometimes the pioneer doesn't finish the trail. Sometimes the pioneer builds a new one.
Clinical & Regulatory
4 min read
Two Shots a Year. Two Infections Out of 2,180 People.
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 people in the PURPOSE 2 trial, crushing daily Truvada by 89%. The science is settled; now comes the hard part.
